About

At BioPhy Capital Management we go beyond traditional fundamental analysis. We seek to evaluate and understand the scientific potential of a company’s drug pipeline to inform where, when, and how we invest in the biotech sector. The BioPhy team has developed an innovative technology that analyzes drugs currently undergoing clinical trials and predicts the likelihood of their success. We believe with those insights, our proprietary Scientific Quant investment approach enables investors to capitalize on the widespread mispricing of clinical-trial-stage biotechnology companies in the market.